{"contentid": 488442, "importid": NaN, "name": "Zydus COVID-19 drug gets EUA from Indian regulator as cases spiral", "introduction": "Indian drugmaker Zydus Cadila has received restricted emergency use approval (EUA) from the Drug Controller General of India (DCGI) for the use of Virafin (pegylated interferon alpha-2b) in treating moderate COVID-19 infection in adults.", "content": "<p>Indian drugmaker Zydus Cadila (NSE: CADILAHC) has received restricted emergency use approval (EUA) from the Drug Controller General of India (DCGI) for the use of Virafin (pegylated interferon alpha-2b) in treating moderate COVID-19 infection in adults.</p>\n<p>When administered early on during COVID-19, Virafin will help patients recover faster and avoid many of the complications, the company claims.</p>\n<p>Virafin, which has shown efficacy in Phase II and Phase III trials, will be available on the prescription of medical specialists for use in India&rsquo;s hospitals, many of which are struggling to cope with the volume of COVID-19 patients. New cases currently number around 300,000 per day in the Asian country.</p>\n<p>In a multicenter trial conducted in 20 to 25 centers across India, Virafin has been shown to reduce the need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19. The drug has also shown efficacy against other viral infections.</p>\n<p>Sharvil Patel, managing director, Cadila Healthcare Limited, said: &ldquo;The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19.&rdquo;</p>\n<p>Zydus has been supported by India's Biotechnology Industry Research Assistance Council&nbsp;in its development of Virafin for the treatment of COVID-19.</p>", "date": "2021-04-23 18:05:00", "meta_title": NaN, "meta_keywords": "COVID-, Virafin, drug, Zydus, Indian, India, Cadila, treating, cases, regulator, spiral, adults, infection, moderate, interferon, pegylated, alpha-b, DCGI", "meta_description": "Indian drugmaker Zydus Cadila has received restricted emergency use approval (EUA) from the Drug Controller General of India (DCGI) for the use of Virafin (pegy", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-23 17:59:47", "updated": "2021-04-24 11:13:08", "access": NaN, "url": "https://www.thepharmaletter.com/article/zydus-covid-19-drug-gets-eua-from-indian-regulator-as-cases-spiral", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "zydus-big-1.png", "image2id": "zydus-small-1.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases", "topic_tag": "Coronavirus, Focus On, Regulation", "geography_tag": "India", "company_tag": "Zydus Cadila", "drug_tag": "Virafin", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-23 18:05:00"}